Background: Patients with asthma usually present airway inflammation classified as eosinophilic, neutrophilic, mixed granulocytic, and paucigranulocytic pattern according to sputum inflammatory cells. Objective: The aim of the study was to analyze clinical and biological characteristics of patients with asthma and mixed granulocytic pattern in comparison with the other groups. Methods: Induced sputum was used to assess airway inflammation; lung function was evaluated as well as blood leukocytes and disease control. History of comorbidities was collected. Results: We retrospectively analyzed 231 subjects with asthma; patients with mixed granulocytic pattern were more frequently male compared with paucigranulocytic subjects, older than eosinophilic and paucigranulocytic patients with increased number and vitality of sputum cells compared to eosinophilic and paucigranulocytic patients and higher cumulative illness rating score, related to increased age. Smoking history, age of disease onset, and ICS treatment were not associated with higher mixed granulocytic pattern occurrence. Subjects with neutrophilic inflammation (mixed granulocytic and neutrophilic patterns considered altogether) were more frequently obese. In subjects under 67 years of age (median of the enrolled subjects), arterial hypertension was the only comorbidity more frequent in mixed granulocytic than in the other groups. 137/231 subjects were re-valuated during follow-up. Lung function of patients with mixed granulocytic, neutrophilic, and paucigranulocytic patterns improved less than that of eosinophilic patients. Conclusion: Aging and presence of comorbidities, in particular obesity and hypertension, are characteristics of patients with asthma and mixed granulocytic pattern. They could respond less well to treatment than eosinophilic patients.

Keywords:
Asthma, Airway inflammation, Phenotype, Granulocytic pattern
1.
Global Initiative for Asthma. GINA report, global strategy for asthma management and prevention (2021 update). 2021. [Cited: 11 February 2022]. Available from: https://ginasthma.org/gina-reports.
2.
Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, et al. Erratum: T-helper type 2–driven inflammation defines major subphenotypes of asthma.
Am J Respir Crit Care Medam J Respir Crit Care Med
. 2009 Sep;180(58):388–95.
3.
Abdala-Valencia H, Coden ME, Chiarella SE, Jacobsen EA, Bochner BS, Lee JJ, et al. Shaping eosinophil identity in the tissue contexts of development, homeostasis, and disease.
J Leukoc Biol
. 2018 Jul;104(1):95–108.
4.
Spanevello A, Confalonieri M, Sulotto F, Romano F, Balzano G, Migliori GB, et al. Induced sputum cellularity. Reference values and distribution in normal volunteers.
Am J Respir Crit Care Med
. 2000 Sep;162(3):1172–4.
5.
Nair P, Surette MG, Virchow JC. Neutrophilic asthma: misconception or misnomer?
Lancet Respir Med
. 2021 May;9(5):441–3.
6.
Gibson PG. Inflammatory phenotypes in adult asthma: clinical applications.
Clin Respir J
. 2009 Oct;3(4):198–206.
7.
Louis R, Lau LC, Bron AO, Roldaan AC, Radermecker M, Djukanović R. The relationship between airways inflammation and asthma severity.
Am J Respir Crit Care Med
. 2000 Jan;161(1):9–16.
8.
The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European network for understanding mechanisms of severe asthma.
Eur Respir J
. 2003 Sep;22(3):470–7.
9.
Hastie AT, Moore WC, Meyers DA, Vestal PL, Li H, Peters SP, et al. Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes.
J Allergy Clin Immunol
. 2010 May;125(5):1028–36.e13.
10.
Hastie AT, Mauger DT, Denlinger LC, Coverstone A, Castro M, Erzurum S, et al. Mixed sputum granulocyte longitudinal impact on lung function in the severe asthma research program.
Am J Respir Crit Care Med
. 2021 Apr 1;203(7):882–92.
11.
Azim A, Freeman A, Lavenu A, Mistry H, Haitchi HM, Newell C, et al. New perspectives on difficult asthma; sex and age of asthma-onset based phenotypes.
J Allergy Clin Immunol In Pract
. 2020 Nov-Dec;8(10):3396–406.e4.
12.
Ind P, Chanez P, Holz O, Djukanovic R, Sterk P, Maestrelli P, et al. Sputum induction.
Eur Respir J
. 2002 Sep;20(Suppl 37):3s–8s.
13.
Pizzichini M, Kelly M, Hamid Q, Pizzichini E, Linden M, Louis R, et al. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation.
Eur Respir J
. 2002;20(Suppl 37):19s–23s.
14.
Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum.
Respirology
. 2006 Jan;11(1):54–61.
15.
Culver BH, Graham BL, Coates AL, Wanger J, Berry CE, Clarke PK, et al. Recommendations for a standardized pulmonary function report. An official American thoracic society technical statement.
Am J Respir Crit Care Med
. 2017 Dec 1;196(11):1463–72.
16.
Schleich F, Graff S, Guissard F, Henket M, Paulus V, Louis R. Asthma in elderly is characterized by increased sputum neutrophils, lower airway caliber variability and air trapping.
Respir Res
. 2021 Jan 13;22(1):15.
17.
Pignatti P, Ragnoli B, Radaeli A, Moscato G, Malerba M. Age-related increase of airway neutrophils in older healthy nonsmoking subjects.
Rejuvenation Res
. 2011 Aug;14(4):365–70.
18.
Thomas RA, Green RH, Brightling CE, Birring SS, Parker D, Wardlaw AJ, et al. The influence of age on induced sputum differential cell counts in normal subjects.
Chest
. 2004 Dec;126(6):1811–4.
19.
Bullone M, Carriero V, Bertolini F, Folino A, Mannelli A, Di Stefano A, et al. Elevated serum IgE, oral corticosteroid dependence and IL-17/22 expression in highly neutrophilic asthma.
Eur Respir J
. 2019 Nov 7;54(5):1900068.
20.
Lommatzsch M, Klein M, Stoll P, Virchow JC. Impact of an increase in the inhaled corticosteroid dose on blood eosinophils in asthma.
Thorax
. 2019 Apr;74(4):417–8.
21.
Hastie AT, Mauger DT, Denlinger LC, Coverstone A, Castro M, Erzurum S, et al. Baseline sputum eosinophil + neutrophil subgroups’ clinical characteristics and longitudinal trajectories for NHLBI Severe Asthma Research Program (SARP 3) cohort.
J Allergy Clin Immunol
. 2020 Jul;146(1):222–6.
22.
Shi B, Li W, Dong H, Xu M, Hao Y, Gao P. Distribution of inflammatory phenotypes among patients with asthma in Jilin Province, China: a cross-sectional study.
BMC Pulm Med
. 2021 Nov 12;21(1):364.
23.
Schleich F, Brusselle G, Louis R, Vandenplas O, Michils A, Pilette C, et al. Heterogeneity of phenotypes in severe asthmatics. The Belgian severe asthma registry (BSAR).
Respir Med X
. 2014 Dec;108(12):1723–32.
24.
Lommatzsch M, Klein M, Stoll P, Virchow JC. Type 2 biomarker expression (FeNO and blood eosinophils) is higher in severe adult-onset than in severe early-onset asthma.
Allergy
. 2021 Oct;76(10):3199–202.
25.
Newby C, Agbetile J, Hargadon B, Monteiro W, Green R, Pavord I, et al. Lung function decline and variable airway inflammatory pattern: longitudinal analysis of severe asthma.
J Allergy Clin Immunol
. 2014 Aug;134(2):287–94.e5.
26.
Abdel-Aziz MI, Brinkman P, Vijverberg SJH, Neerincx AH, Riley JH, Bates S, et al.; U-BIOPRED Study Group. Sputum microbiome profiles identify severe asthma phenotypes of relative stability at 12 to 18 months.
J Allergy Clin Immunol
. 2021 Jan;147(1):123–34.
27.
Singhania A, Wallington JC, Smith CG, Horowitz D, Staples KJ, Howarth PH, et al. Multitissue transcriptomics delineates the diversity of airway T cell functions in asthma.
Am J Respir Cell Mol Biol
. 2018 Feb;58(2):261–70.
28.
Singhal A, Kumar S. Neutrophil and remnant clearance in immunity and inflammation.
Immunology
. 2022 Jan;165(1):22–43.
29.
Mincham KT, Bruno N, Singanayagam A, Snelgrove RJ. Our evolving view of neutrophils in defining the pathology of chronic lung disease.
Immunology
. 2021 Dec;164(4):701–21.
30.
Niessen NM, Gibson PG, Baines KJ, Barker D, Yang IA, Upham JW, et al. Sputum TNF markers are increased in neutrophilic and severe asthma and are reduced by azithromycin treatment.
Allergy
. 2021 Jul;76(7):2090–101.
31.
Thomson NC, Chaudhuri R, Heaney LG, Bucknall C, Niven RM, Brightling CE, et al. Clinical outcomes and inflammatory biomarkers in current smokers and exsmokers with severe asthma.
J Allergy Clin Immunol
. 2013 Apr;131(4):1008–16.
32.
Klein DK, Silberbrandt A, Frøssing L, Hvidtfeldt M, von Bülow A, Nair P, et al. Impact of former smoking exposure on airway eosinophilic activation and autoimmunity in patients with severe asthma.
Eur Respir J
. 2022 Mar 2;60(4):2102446.
33.
Albataineh E, Al-Zayadneh E, Al-Shagahin H, Al Soloman A, Altarawneh A, Aldmour I. Correction to: asthma control and its predictive factors in adult asthma patients.
J Clin Med Resj Clin Med Res
. 2020 Feb;12(2):127.
34.
Scott HA, Gibson PG, Garg ML, Wood LG. Airway inflammation is augmented by obesity and fatty acids in asthma.
Eur Respir J
. 2011 Sep;38(3):594–602.
35.
Telenga ED, Tideman SW, Kerstjens HAM, Hacken NHTt, Timens W, Postma DS, et al. Obesity in asthma: more neutrophilic inflammation as a possible explanation for a reduced treatment response.
Allergy
. 2012 Aug;67(8):1060–8.
36.
Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI, Lloyd-Jones D, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment--a position paper of the the Obesity Society and the American Society of Hypertension.
Obesity
. 2013 Jan;21(1):8–24.
37.
Christiansen SC, Zuraw BL. Treatment of hypertension in patients with asthma.
N Engl J Med
. 2019 Sep 12;381(11):1046–57.
© 2022 S. Karger AG, Basel
2022
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.